Zylox-Tonbridge to Acquire German MedTech Firm Optimed in Global expansion Move
Hong Kong-listed Zylox-Tonbridge is set to acquire German medical technology company Optimed, a strategic move designed to accelerate its global reach in teh neurovascular and peripheral vascular interventional product markets.
Zylox-Tonbridge will acquire Optimed’s equity interest through a multi-step process, with the option to ultimately purchase the entire shareholding from current owners. The acquisition aims to create a unified platform encompassing research and growth, manufacturing, and commercialization, bolstering the company’s position in the rapidly evolving medical device landscape.
Optimed, with nearly 30 years of operational experiance, specializes in the research, development, production, and distribution of devices for minimally invasive therapies worldwide. The company boasts an established sales and service network spanning over 70 countries, a key asset Zylox-Tonbridge intends to leverage.
Peripheral Venous Stenting expertise
Optimed’s product portfolio focuses heavily on the peripheral venous stenting segment, offering devices specifically designed for challenging vascular anatomies, including the iliofemoral veins, vena cava, and iliac bifurcation. Clinical data supporting the efficacy of Optimed’s venous stents comes from trials such as sinus-Venous and STEVECO – the first prospective, multicentre, randomised study in chronic deep venous obstruction.
Results from these trials demonstrated important improvements in patients’ quality of life and clinical severity when compared to conservative treatment approaches. this robust clinical evidence underscores the potential value Optimed brings to Zylox-Tonbridge’s offerings.
Synergies and Future Growth
According to a company release, the acquisition is expected to generate operational synergies through an expanded manufacturing base in Germany. This will ensure a reliable supply of medical solutions for both European and global markets. Following the transaction’s completion, Zylox-Tonbridge plans to integrate the sales, marketing, and customer service teams of both companies, establishing a unified global commercial organization.
Rüdiger Hausherr will continue to serve as CEO of optimed, reporting directly to Dr. Jonathon Zhong zhao, chairman and CEO of Zylox-Tonbridge.
“This acquisition marks an important milestone in Zylox-Tonbridge’s global strategy, enabling the company to leverage a broader European-based platform to accelerate its global expansion,” Zhao stated. “We are vrey pleased to welcome Optimed to the Zylox-Tonbridge Group and look forward to combining our complementary product portfolios and manufacturing platforms to bring high-quality, innovative and affordable solutions to more patients and physicians worldwide, while driving the company’s next phase of growth.”
The partnership signifies a commitment to innovation and accessibility in the medical device industry,positioning Zylox-Tonbridge for continued growth and impact on a global scale.
here’s a breakdown answering the “Why, Who, What, and How” questions, transforming the update into a substantive news report:
Why: Zylox-Tonbridge is acquiring Optimed to accelerate its global expansion, notably in the neurovascular and peripheral vascular interventional product markets. The move aims to leverage Optimed’s established European presence and expertise in peripheral venous stenting.
Who: Zylox-tonbridge, a Hong Kong-listed medical technology company, is acquiring Optimed, a German medical technology firm specializing in
